TY - JOUR
T1 - Durability of antibody response to vaccination and surrogate neutralization of emerging variants based on SARS-CoV-2 exposure history
AU - McDade, Thomas W.
AU - Demonbreun, Alexis R.
AU - Sancilio, Amelia
AU - Mustanski, Brian
AU - D’Aquila, Richard T.
AU - McNally, Elizabeth M.
N1 - Funding Information:
Financial support for this research from the National Science Foundation (BCS-2035114), National Institutes of Health (3UL1TR001422-06S4), and the Northwestern University Office of Research is gratefully acknowledged. The funding sources had no role in the study design, data collection, analysis, interpretation, or writing of the report.
Publisher Copyright:
© 2021, The Author(s).
PY - 2021/12
Y1 - 2021/12
N2 - Two-dose messenger RNA vaccines against the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) are highly effective in preventing symptomatic COVID-19 infection. However, the durability of protection is not known, nor is the effectiveness against emerging viral variants. Additionally, vaccine responses may differ based on prior SARS-CoV-2 exposure history. To investigate protection against SARS-CoV-2 variants we measured binding and neutralizing antibody responses following both vaccine doses. We document significant declines in antibody levels three months post-vaccination, and reduced neutralization of emerging variants, highlighting the need to identify correlates of clinical protection to inform the timing of and indications for booster vaccination.
AB - Two-dose messenger RNA vaccines against the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) are highly effective in preventing symptomatic COVID-19 infection. However, the durability of protection is not known, nor is the effectiveness against emerging viral variants. Additionally, vaccine responses may differ based on prior SARS-CoV-2 exposure history. To investigate protection against SARS-CoV-2 variants we measured binding and neutralizing antibody responses following both vaccine doses. We document significant declines in antibody levels three months post-vaccination, and reduced neutralization of emerging variants, highlighting the need to identify correlates of clinical protection to inform the timing of and indications for booster vaccination.
UR - http://www.scopus.com/inward/record.url?scp=85113867543&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85113867543&partnerID=8YFLogxK
U2 - 10.1038/s41598-021-96879-3
DO - 10.1038/s41598-021-96879-3
M3 - Article
C2 - 34462501
AN - SCOPUS:85113867543
SN - 2045-2322
VL - 11
JO - Scientific Reports
JF - Scientific Reports
IS - 1
M1 - 17325
ER -
